Millennium PGTSM is a non-invasive genetic test utilizing an oral swab to identify how a patient’s genetic profile may impact his or her response to certain medications. Two patients, with the same diagnosis and prescribed the same medication and dose, may exhibit significantly different clinical responses.
The information from the test may provide health care providers a faster and more effective path to optimal medication management.
A swab is used to collect a DNA sample from oral fluid
Our specialty lab performs genetic testing on the specimen
The DNA is analyzed and a report is generated with results interpretation
Pharmacists and genetic scientists are available for clinical guidance
Millennium PGTSM analyzes clinically relevant genetic variants for 14 genes related to medication response to help clinicians individualize prescribing decisions. The Millennium Analysis of Patient Phenotype (MAPP) Report provides clinicians with evidence based and clinically actionable information to support medication decisions for over 40 commonly prescribed medications across 12 medication classes.
| Addiction Therapy Anticoagulants Anticonvulsants Antidepressants, SSRIs/SNRIs Antidepressants, TCAs Antipsychotics | ADHD Therapy Benzodiazepines Muscle Relaxants NSAIDs Opioids Platelet Inhibitors |
| COMT CYP2B6 CYP2C19 CYP2C9 CYP2D6 CYP3A4 CYP3A5 | DRD2 HLA-B HTR2C MTHFR OPRM1 UGT2B15 VKORC1 |
The Millennium Analysis of Patient Phenotype (MAPP) Report provides clinicians with evidence-based and clinically actionable genetic information to support medication decisions. It can be broken down into three main sections:
1. Laboratory Test Results:
Indicates which gene tests were ordered and the corresponding test results.
2. Current Medication Summary:
An interpretation of your patient’s genetic test results as it relates to his/her current reported medications, highlighting medication(s) that may need attention, and relevant CYP450 drug-drug interactions.
3. Medication Selection Guide:
An objective tool that can be used to inform prescribing decisions according to the patient’s genetic test results.
Identifies medications that may have a high clinical impact based on the patient’s genetic test results.
Identifies medications that may have moderate clinical impact based on the patient’s genetic test results.
Identifies medications in which the patient is likely to have a typical response based on patient’s genetic test results.
Identifies medications for which the patient is likely to have an improved or enhanced response based on patient’s genetic test results.
Identifies potential cytochrome P450 interactions based on patient’s reported medications.
Millennium PGT results are integrated with Millennium UDT results to enhance medication monitoring.
Brian suffered from depression for 25 years, and just like many other mental health patients, he was prescribed many medications that were ineffective. Looking for new therapies to combat his illness, he found Dr. Edgar Castillo-Armas, a clinician who has gone beyond the trial and error approach.
After Samantha suffered a fractured femur, her physician suggested pharmacogenetic testing (PGT) helped manage her pain and prescribe the right medication at the right time. Like many patients, Samantha was caught in the trial-and-error approach to prescribing medication, continuing to respond negatively to prescription medications.
Pharmacogenetic testing helped Lisa’s physician prescribe the right pain medication at the right time. Too many patients rely on medication trial and error – prescribing medicine and observing patient response. As Lisa attempted to manage her pain with ineffective medication, her physician suggested Millennium PGT to predict Lisa’s likely response to a variety of prescription medications.
Millennium Health, LLC tests were developed and their performance characteristics determined by Millennium Health. These tests have not been cleared or approved by the US Food and Drug Administration. FDA clearance or approval is not required for clinical use. Millennium Health is regulated under CLIA as qualified to perform high-complexity testing, and is accredited by the College of American Pathologists (CAP). These tests are used for clinical purposes and should not be regarded as investigational or for research. The test results should be used with other clinical and diagnostic findings for patient case management.
